Brad Eilerman, M.D.

Board certified physician in obesity medicine, endocrinology, diabetes, and metabolism. Co-founder of PATH Decision Support Software.

[Brad Eilerman, M.D. @endocrine]

@mcuban I’ve been a fan for your work in this area for a while, but this has been your best post with a clear understanding of the dynamics.

[Brad Eilerman, M.D. @endocrine]

@mcuban incredible talk at #AMGA. You definitely “get it”. I have stories that match all of the insanity that you describe. It seems like the heart of the problem are the people negotiating benefits that are satisfied with an inherently inferior product.

[Brad Eilerman, M.D. @endocrine]

https://t.co/OP04VH9EYP

[Brad Eilerman, M.D. @endocrine]

Watched incretin weight loss spread through our organization. One patient drops 40lbs, three coworkers request scripts. Visible proof drove demand vertical. At $1K/month the math broke. Coverage ended. Effective therapy succeeded itself out of the formulary.

[Brad Eilerman, M.D. @endocrine]

@ballen63 @chamath Did that make you feel superior?

[American Diabetes Association - DiabetesPro @ADA_DiabetesPro]

🚨 PRESS RELEASE: One in four patients with difficult-to-control T2D have high cortisol levels, according to the CATALYST study. Learn more about this groundbreaking research presented at #ADASciSessions & its implications for diabetes management here: 🔗 https://t.co/CeT9VmluPu

[Brad Eilerman, M.D. @endocrine]

@RealPatCampbell Amazing presentation today at ADA with groundbreaking data

[Patrick Campbell @RealPatCampbell]

At #ADASciSessions Dr. DeFronzo underscores the role of hypercortisolism in difficult-to-control type 2 diabetes by suggesting it may be time to revise his famous "Ominous Octet" with the "Noxious Nine".

Hear more from Dr. DeFronzo:
https://t.co/Rb8qkMibkn

#T2D #Diabetes

[Brad Eilerman, M.D. @endocrine]

Catalyst trial changing the face of diabetes #NoxiousNine

[Brad Eilerman, M.D. @endocrine]

Demystifying Drug Costs: A Guide for Patients https://t.co/yjGcwcwGTz

[Brad Eilerman, M.D. @endocrine]

@Jason Jason, I don’t know you and I’m sure this will get lost in a sea of replies, but I can say from your public persona that you seem like a person of high character with a special ability to listen and consider different opinions. We are lucky to have you the the discourse

[Brad Eilerman, M.D. @endocrine]

Semaglutide Shakes Up Cardio Health: The SELECT Trial https://t.co/Btx8R16mvr

[Brad Eilerman, M.D. @endocrine]

Breaking News in Diabetes Care: The FLOW Trial and The Rising Star of GLP-1 Agonists https://t.co/1mn8to6OCK

[Brad Eilerman, M.D. @endocrine]

Embracing Autumn: A Seasonal Guide for People with Diabetes https://t.co/XErZ7c5lL9

[Brad Eilerman, M.D. @endocrine]

Wegovy/semaglutide cardiovascular should generate a fundamental shift from insurers regarding the treatment of Cardiometabolic disease. I suspect the shift will rocky. #select

[Brad Eilerman, M.D. @endocrine]

Navigating Emotional Stressors with Diabetes: A Holistic Approach https://t.co/5GShhf6SR9

[Brad Eilerman, M.D. @endocrine]

The Dangers of the Medical "Hot Take": Unraveling the Metformin and Statins Narrative https://t.co/0WPuQsqtIf

[Brad Eilerman, M.D. @endocrine]

A Deep Dive into Adrenal Health: Understanding Adrenal Fatigue and Recognized Adrenal Disorders https://t.co/gy3YLA5Gat

[Brad Eilerman, M.D. @endocrine]

Comprehensive Guide to Vaccinations for Individuals Living with Diabetes https://t.co/vDIYf7pAIE

[Brad Eilerman, M.D. @endocrine]

Breaking Down Hypoglycemia: A Simple Guide to Diagnosis and Testing https://t.co/hes4hizIvk